Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02973477 · ClinicalTrials.gov registry record · Phase 4
Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)
A Phase 4 study of Cardiovascular Diseases and Type2 Diabetes, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 4
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT02973477 is a Phase 4 study of Cardiovascular Diseases and Type2 Diabetes that has completed, run by University of Michigan. The registered enrollment target is 45 participants, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02973477, a Phase 4 study of Cardiovascular Diseases and Type2 Diabetes, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of dapagliflozin, a FDA approved diabetes medication, on measures of nervous system function of the heart in patients with type 2 diabetes. The investigators will compare the effect of dapagliflozin with an active comparator, glimepiride (a different FDA approved diabetes medication) on measures of heart rate variability and assess whether dapagliflozin has modulating effects on measures of nervous system function of the heart. This is a crossover study design where all participants will receive both study medications equally (12-week intervention periods) in a certain order.
Conditions Studied
Interventions
- DRUG Dapagliflozin
- DRUG Glimepiride
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-01-12 |
| Est. Completion | 2019-08-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02973477
The ClinicalTrials.gov registry entry for NCT02973477 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,974-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (100% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT02973477 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02973477 about?
NCT02973477 is a clinical study titled "Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)". The purpose of this study is to evaluate the effect of dapagliflozin, a FDA approved diabetes medication, on measures of nervous system function of the heart in patients with type 2 diabetes. The investigators will compare the effect of dapagliflozin with an active comparator, glimepiride (a differe...
What is the current status of trial NCT02973477?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 45 participants. The study started on 2017-01-12. Estimated completion is 2019-08-22.
What conditions does trial NCT02973477 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Type2 Diabetes.
What interventions are being tested in trial NCT02973477?
The interventions under investigation include: Dapagliflozin (DRUG), Glimepiride (DRUG).
Who is sponsoring clinical trial NCT02973477?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02973477 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
RECRUITING · Phase 4
-
NSAIDs vs. Coxibs in the Presence of Aspirin
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.